Incyte
Clinical trials sponsored by Incyte, explained in plain language.
A biopharmaceutical company focused on oncology and inflammation.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo therapy shows promise for tough-to-treat lymphoma Results expected Sep 2026 (estimated)
- Healthy volunteers help scientists measure how two drugs enter skin and blood Results expected Sep 2026 (estimated)
- New drug shows promise for advanced skin cancer in early trial Results expected Sep 2026 (estimated)
- New hope for advanced tumors: drug trial targets untreated patients Results expected Sep 2026 (estimated)
- New cream could ease painful skin bumps for HS sufferers Results expected Oct 2026 (estimated)
-
Can a new drug extend remission in advanced ovarian cancer?
Disease control Not yet recruitingThis trial tests whether adding an experimental drug called INCB123667 to the standard maintenance therapy bevacizumab can delay cancer recurrence in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. Participants must have completed initial chemotherapy …
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a new drug wipe out hidden cancer DNA and stop colorectal cancer from returning?
Prevention Not yet recruitingResearchers are testing an experimental drug called INCA33890 in people with stage II or III colorectal cancer who have finished surgery and chemotherapy but still have tiny amounts of tumor DNA in their blood. This leftover DNA, called circulating tumor DNA or ctDNA, can signal …
Phase 2 • Sponsor: Incyte Corporation • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Radioactive tracer maps where a new drug goes in the body
Knowledge-focused Not yet recruitingResearchers want to know how the body absorbs, breaks down, and clears an experimental oral drug called INCB161734. They give a single dose to 10 healthy men aged 19 to 55, tagging part of the drug with a tiny radioactive tracer. By measuring the tracer in blood, urine, and stool…
Phase 1 • Sponsor: Incyte Corporation • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC